Alumis Inc (ALMS)

$5.52 +0.24 (4.55%)
Market Cap 549.46M
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,721,600
Avg Vol 669,468
Day's Range N/A - N/A
Shares Out 104.06M
Stochastic %K 90%
Beta -1.33
Analysts Strong Sell
Price Target $19.00

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
StockScanners
StockScanners Nov. 15 at 4:07 AM
$ALMS keep watch if this holds above 5.40
0 · Reply
777Dog
777Dog Nov. 14 at 5:05 PM
$ALMS looks like I am wrong… good news for longs
1 · Reply
777Dog
777Dog Nov. 14 at 2:21 PM
$ALMS jump over $5 may have been head-fake…hope not, but who knows Please correct if wrong, but Tak-279 p3 just completed… Goliath is likely pumped… Takeda completes a phase III trial in Plaque psoriasis in USA, Australia, Canada… I lightened up pending Takeda filing since they now have a full deck, and we are in need of a completion date…and updates!
1 · Reply
IN0V8
IN0V8 Nov. 11 at 7:29 PM
$ALMS people catching up - or making a mistake?
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 11 at 6:53 PM
$ALMS nice updates at gugg
1 · Reply
laaarsas
laaarsas Nov. 11 at 3:53 PM
$ALMS are we up last week bcuz of investor conference marketing?
0 · Reply
JazzyJ03
JazzyJ03 Nov. 10 at 9:32 PM
$ALMS nice close
0 · Reply
laaarsas
laaarsas Nov. 10 at 2:16 AM
$ALMS what ppl think of upcoming ONWARD ?
0 · Reply
laaarsas
laaarsas Nov. 6 at 4:56 PM
$ALMS What to ppl think about competetion here? Is icotrokinra the best oral option we are competing with? We will not beat that. Is there still a market for EKS-001? If yes, why? What is that market?
0 · Reply
laaarsas
laaarsas Nov. 5 at 4:50 AM
$ALMS there was a fusion with Acelyrin in May this year, is that right? What do people think of that? Good or bad?
1 · Reply
Latest News on ALMS
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 1 day ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 10 days ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 2 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 2 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 3 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 4 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 4 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 6 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 6 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 6 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 6 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 6 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 7 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 7 months ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 7 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 8 months ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 8 months ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 8 months ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 8 months ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 8 months ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 9 months ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 9 months ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 9 months ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 9 months ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 9 months ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 10 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 10 months ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 10 months ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

Jul 1, 2024, 11:51 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions

AGH INHI LB LINE TBN TWFG WBTN

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Jun 28, 2024, 1:36 PM EDT - 1 year ago

Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 1 year ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 1 year ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 1 year ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 1 year ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 1 year ago

Alumis eyes $300 million in proceeds in IPO

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

Jun 11, 2024, 12:25 PM EDT - 1 year ago

Alumis' $100 Million IPO: Promising Psoriasis Treatment Results

StockScanners
StockScanners Nov. 15 at 4:07 AM
$ALMS keep watch if this holds above 5.40
0 · Reply
777Dog
777Dog Nov. 14 at 5:05 PM
$ALMS looks like I am wrong… good news for longs
1 · Reply
777Dog
777Dog Nov. 14 at 2:21 PM
$ALMS jump over $5 may have been head-fake…hope not, but who knows Please correct if wrong, but Tak-279 p3 just completed… Goliath is likely pumped… Takeda completes a phase III trial in Plaque psoriasis in USA, Australia, Canada… I lightened up pending Takeda filing since they now have a full deck, and we are in need of a completion date…and updates!
1 · Reply
IN0V8
IN0V8 Nov. 11 at 7:29 PM
$ALMS people catching up - or making a mistake?
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 11 at 6:53 PM
$ALMS nice updates at gugg
1 · Reply
laaarsas
laaarsas Nov. 11 at 3:53 PM
$ALMS are we up last week bcuz of investor conference marketing?
0 · Reply
JazzyJ03
JazzyJ03 Nov. 10 at 9:32 PM
$ALMS nice close
0 · Reply
laaarsas
laaarsas Nov. 10 at 2:16 AM
$ALMS what ppl think of upcoming ONWARD ?
0 · Reply
laaarsas
laaarsas Nov. 6 at 4:56 PM
$ALMS What to ppl think about competetion here? Is icotrokinra the best oral option we are competing with? We will not beat that. Is there still a market for EKS-001? If yes, why? What is that market?
0 · Reply
laaarsas
laaarsas Nov. 5 at 4:50 AM
$ALMS there was a fusion with Acelyrin in May this year, is that right? What do people think of that? Good or bad?
1 · Reply
BIOTECH_GURU
BIOTECH_GURU Nov. 4 at 1:55 AM
$TERN if you want another exciting play for possible 3-10x $ALMS pending p3 data. P2 data was rock solid. They have an exciting pipeline that may be very similar to NKTR. $PRME bottom of a channel play, likely bounce to 6 very soon. Gene editing play. $ALT pending p2 data. Best in class for MASH IMO. $CAPR do or die time with their P3 data. Exciting times to be a biotech investor as fiscal policy swing will continue to be a catalyst.
1 · Reply
laaarsas
laaarsas Nov. 2 at 2:45 PM
$ALMS very little activity here, strange
0 · Reply
laaarsas
laaarsas Nov. 1 at 2:36 PM
$ALMS how high will this stock go if phase 3 is positive? do you think the competition in this space is a problem for ALMS?
1 · Reply
777Dog
777Dog Oct. 31 at 1:32 PM
$ALMS nice summary of 001 https://sigma.larvol.com/product.php?e1=934407&tab=newstrac
0 · Reply
24oldmillclear
24oldmillclear Oct. 15 at 1:15 PM
$ALMS
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 12:31 PM
$ALMS 🫡join the winning team
0 · Reply
Winning_calls
Winning_calls Oct. 13 at 3:46 AM
$ALMS pick me up @ $4.40
0 · Reply
10xby3
10xby3 Oct. 8 at 11:52 AM
$ALMS here we go! 200 day MA watch today and then $6 plus
0 · Reply
SmartMoneyTradez
SmartMoneyTradez Oct. 7 at 9:05 PM
$ALMS 20/50 ma breakout with volume - Insider action $TMC running on volume . Canada primer visited today. ca stocks such as $POET pumping as well Expecting continuation run into the am
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 7 at 5:32 PM
$ALMS just popped 3% higher to 9% (~1Mv) moments ago, 10/17 options, follow for more volatility.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Oct. 4 at 11:45 PM
$ALMS reviewed their data. Very high likelihood of success. I will buy a shit ton if it dips. I expect this to be trading in the 20s once trial data is announced. ****nfa**** Good luck all.
0 · Reply
TalkMarkets
TalkMarkets Sep. 29 at 10:05 PM
Bargain Hunters’ Delight: Four Stocks Trading Below Cash Per Share With Minimal Debt $GDOT $ARVN $KROS $ALMS https://talkmarkets.com/content/stocks--equities/bargain-hunters-delight-four-stocks-trading-below-cash-per-share-with-minimal-debt?post=525519
0 · Reply